Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biovail Signs Deals With Acadia, GSK

by Rick Mullin
May 11, 2009 | A version of this story appeared in Volume 87, Issue 19

Biovail and Acadia Pharmaceuticals are joining to commercialize pimavanserin, a drug developed by Acadia to treat psychosis caused by Parkinson's disease. It is currently in Phase III clinical trials. Biovail will make a $30 million up-front payment plus milestone payments for commercial achievements. Acadia could get up to $395 million. Separately, Biovail will acquire U.S. rights to GlaxoSmithKline's antidepressant Wellbutrin XL for $510 million. The drug, now off patent, was developed by Biovail.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.